Borui Pharmaceuticals: BGM0504 Tablets for Weight Loss Achieves Positive Results in Phase I Clinical Trial

Ask AI · How will Borui Pharmaceuticals optimize subsequent clinical trials based on Phase I results?

On March 24, Borui Pharmaceuticals (688166.SH) announced that the GLP-1/GIP dual receptor agonist BGM0504 tablets, independently developed by the company, achieved positive results in Phase I clinical trials conducted in China and the United States for the treatment of adult overweight/obesity. The Phase I trial in China enrolled 75 participants, with good safety across all dose groups (10~80mg QD) and no serious adverse events reported. After four weeks of continuous administration, the average weight decreased by 1.04% to 5.56% compared to baseline; the Phase I trial in the United States enrolled 80 participants, and after 5 to 8 weeks of administration at doses of 20~80mg, the weight reduction ranged from 2.7% to 8.2%, with no serious adverse events reported. Both trials demonstrated good safety and preliminary efficacy, supporting the advancement to Phase II clinical research. The company noted that the new drug development cycle is long and high-risk, with no significant impact on operations in the short term.